I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231 on 29 ecroser

Patent Application Docket No. USF-T144X Serial No. 10/049,502

Jeff Lloyd, Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1646

Applicant(s)

Said M. Sebti

Serial No.

10/049,502

Filed

February 15, 2002

For

RECEIVED

NOV 0 6 2002

TECH CENTER 1600/2900 RhoB as a Suppressor of Cancer Cell Growth and Cell Transformation

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR §§1.97 AND 1.98</u>

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted.

JeffLlov Patent Attorney

Registration No. 35,589

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address:


2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

JL/srp

Enclosures as stated above





eduction Act of 1999 Cho CENTER 1600/2900

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OM

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

Filing Date

Reduction Act of 1999, he persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known

Application Number 10/049,502

February 15, 2002

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Art Unit 1646

Examiner Name (not yet assigned)

Sheet 1 of 2 Attorney Docket Number USF-T144X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US			
	U9	US-			
	U10	US-	<u> </u>		
	U11	US-			
	U12	US-			
	U13	US-			
	U14	ŪS-			
	U15	US-			
	U16	US-	<u> </u>		
	U17	US-	<u> </u>		
	U18	US-	<u> </u>		
	U19	US-		L	
	U20	US-	5		

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document			Pages, Columns, Lines,	
Examiner Initials*	Cite No. 1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F 7					
	F8					
	F9					
	F10					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Kind of document by the English language Translation is attached.



control number

Sheet

RECEIVED

NOV 0 6 2002

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

TECH CENTER 1600/2900

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1900 persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

Paperwork Reduction Act of

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known			
Application Number 10/049,502			
Filing Date	February 15, 2002		
First Named Inventor	Said M. Sebti		
Group Art Unit	1646		
Examiner Name	(not yet assigned)		
Attorney Docket Number	USF-T144X		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CHEN, Z. et al., Farnesylated and Geranylgeranylated RhoB Suppress the Transformation of PANC-1 Human Pancreatic Cancerl Cells; Proceedings of the 91 st Annual Meeting of the American Association for Cancer Research, Volume 14, page 220, abstract no. 1402.	
<u> </u>	R2	DU, W. et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranlyated RhoB, Molecular and Cellular Biology, Volume 19, number 3, March 1999, pages 1831-1840.g	
	R3	CHEN, Z. et al., Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice, Journal of Biological Chemistry, Volume 275, number 24, June 16, 2000, pages 17974-17978.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner	 Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.